Tina England, APRN
Nurse Practitioner · Flatwoods, KYNPI 1760728679
Payments from drug & device makers
Across 181 payments — averaging $17.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$619
- Lilly USA, LLC$434
- Currax Pharmaceuticals LLC$367
- Novo Nordisk$259
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$158
- AstraZeneca$154
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,094100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 48 | $619 |
| Lilly USA, LLC | 28 | $434 |
| Currax Pharmaceuticals LLC | 25 | $367 |
| Novo Nordisk | 12 | $259 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $158 |
| AstraZeneca | 7 | $154 |
| Shield Therapeutics Inc | 2 | $135 |
| Mylan Specialty L.p. | 5 | $134 |
| Pfizer | 7 | $124 |
| Exact Sciences | 6 | $120 |
| Otsuka America Pharmaceutical, Inc. | 5 | $100 |
| GSK | 5 | $85 |
| Novartis | 3 | $60 |
| Merck | 4 | $58 |
| Corcept Therapeutics | 3 | $52 |
| Teva Pharmaceuticals USA, Inc. | 3 | $51 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $50 |
| Boehringer Ingelheim | 2 | $32 |
| Ironshore Pharmaceuticals Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Phadia US Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $12 |
How this compares
$3,094 in reported general payments places this provider in the 85th percentile of 1,918 nurse practitioner providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 117 | $162,364 |
| EliquisApixaban | 94 | $75,843 |
| JardianceEmpagliflozin | 63 | $72,714 |
| MounjaroTirzepatide | 54 | $60,390 |
| TrulicityDulaglutide | 52 | $59,299 |
| JanuviaSitagliptin Phosphate | 38 | $45,970 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $28,767 |
| LinzessLinaclotide | 25 | $26,870 |
| TradjentaLinagliptin | 34 | $22,872 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $10,312 |
| Dexlansoprazole DrDexlansoprazole | 28 | $6,997 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 278 | $5,879 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 126 | $5,015 |
| Vilazodone Hcl | 12 | $4,378 |
| Potassium Chloride | 181 | $3,468 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $259 | $162,364117 claims |
| Lilly USA, LLCMounjaro, Trulicity | $434 | $119,688106 claims |
| Boehringer IngelheimJardiance, Tradjenta | $32 | $95,58597 claims |
| PfizerEliquis | $124 | $75,84394 claims |
| MerckJanuvia | $58 | $45,97038 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $85 | $39,07860 claims |
| AbbVieLinzess, Synthroid | $619 | $29,92268 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,918 nurse practitioner providers in Kentucky.
Other nurse practitioner in Flatwoods
- Rachael BradfordLexington$447K
- Tara MuddLouisville$243K
- Lee HaasLouisville$95K
- Ashley KnableLouisville$86K
- Christina BenningerLouisville$81K
- Courtney BowlingCampbellsville$47K
- Rebecca BraunerLouisville$40K
- Scott SeitzWinchester$34K
- Kristen KreinestEdgewood$34K
- Lillian ArgentEdgewood$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.